Evaluation of multi-assay algorithms for cross-sectional HIV incidence estimation in settings with universal antiretroviral treatment

Wendy Grant-McAuley, Oliver Laeyendecker, Daniel Monaco, Athena Chen, Sarah E. Hudelson, Ethan Klock, Ron Brookmeyer, Douglas Morrison, Estelle Piwowar-Manning, Charles S. Morrison, Richard Hayes, Helen Ayles, Peter Bock, Barry Kosloff, Kwame Shanaube, Nomtha Mandla, Anneen van Deventer, Ingo Ruczinski, Kai Kammers, H. Benjamin Larman, and Susan H. Eshleman

Abstract

Background: Multi-assay algorithms (MAAs) are used to estimate population-level HIV incidence and identify individuals with recent infection. Many MAAs use low viral load (VL) as a biomarker for long-term infection. This could impact incidence estimates in settings with high rates of early HIV treatment initiation. We evaluated the performance of two MAAs that do not include VL.

Methods: Samples were collected from 219 seroconverters (infected < 1 year) and 4376 non-seroconverters (infected > 1 year) in the HPTN 071 (PopART) trial; 28.8% of seroconverter samples and 73.2% of non-seroconverter samples had VLs ≤ 400 copies/mL. Samples were tested with the Limiting Antigen Avidity assay (LAg) and JHU BioRad-Avidity assays. Antibody reactivity to two HIV peptides was measured using the MSD U-PLEX assay. Two MAAs were evaluated that do not include VL: a MAA that includes the LAg-Avidity assay and BioRad-Avidity assay (LAg+BR) and a MAA that includes the LAg-Avidity assay and two peptide biomarkers (LAg+PepPair). Performance of these MAAs was compared to a widely used MAA that includes LAg and VL (LAg+VL).

Results: The incidence estimate for LAg+VL (1.29%, 95% CI: 0.97–1.62) was close to the observed longitudinal incidence (1.34% 95% CI: 1.17–1.53). The incidence estimates for the other two MAAs were higher (LAg+BR: 2.56%, 95% CI: 2.01–3.11; LAg+PepPair: 2.84%, 95% CI: 1.36–4.32). LAg+BR and LAg+PepPair also misclassified more individuals infected > 2 years as recently infected than LAg+VL (1.2% [42/3483] and 1.5% [51/3483], respectively, vs. 0.2% [6/3483]). LAg+BR classified more seroconverters as recently infected than LAg+VL or LAg+PepPair (80 vs. 58 and 50, respectively) and identified ~ 25% of virally suppressed seroconverters as recently infected.

Conclusions: The LAg+VL MAA produced a cross-sectional incidence estimate that was closer to the longitudinal estimate than two MAAs that did not include VL. The LAg+BR MAA classified the greatest number of individual seroconverters as recently infected but had a higher false recent rate.
Background

Multi-assay algorithms (MAAs) have been developed for estimating population-level HIV incidence using samples collected in cross-sectional surveys [1–3]. These algorithms have also been used to identify individuals with recent HIV infection [4–7]. The most widely used MAA includes the Limiting Antigen Avidity assay (LAg-Avidity assay) and HIV viral load (LAg+VL MAA) [8–10]. In this MAA, low HIV viral load is used as a surrogate for antiretroviral treatment (ART). When this MAA was developed, it was based on the assumption that most persons with low viral loads were on ART and were not recently infected, since ART was only initiated later in infection after CD4 cell count decline [8, 10]. Guidelines for ART have since evolved, and ART is now recommended for all persons living with HIV (PLHIV), regardless of CD4 cell count [11]. The World Health Organization, UNAIDS and other groups have set ambitious targets to increase the number of PLHIV who are aware of their HIV status, are on ART, and are virally suppressed [12].

As early ART initiation becomes more widespread, more persons with recent infection will be virally suppressed. This could lead to underestimation of HIV incidence using MAAs that classify these persons as “non-recent”. This type of misclassification is likely to increase over time with scale-up of universal ART. Furthermore, this type of false non-recent misclassification is likely to vary in different regions and populations based on the proportion of persons with recent HIV infection who are aware of their HIV status and are able to access ART and achieve viral suppression early in infection. For these reasons, accurate HIV incidence estimation may require use of MAAs that do not include viral load. Even when viral load is not included as a biomarker, development of MAAs for use in settings with universal ART is challenging, since viral suppression also impacts the performance of the LAg-Avidity assay and other serologic incidence assays [7, 13–16]. This is because the level and avidity of anti-HIV antibodies often decline when persons are virally suppressed on ART [17].

We recently evaluated the impact of universal ART on the performance of the LAg+VL MAA [7, 18] using samples and data from the HIV Prevention Trials Network (HPTN) 071 (PopART) trial [19]. HPTN 071 (PopART) was a community-randomized trial conducted in Zambia and South Africa that demonstrated that universal delivery of a combination prevention intervention that included universal testing and treatment was associated with decreased HIV incidence [19]. Two years after trial onset, ~75% of participants who were infected more than one year and ~30% of those who had acquired HIV infection during the study were virally suppressed [19]. The LAg+VL MAA provided an accurate HIV incidence estimate for this cohort [18], but performed poorly for individual-level recency assessments [7].

In this report, we evaluated the performance of two MAAs that do not include HIV viral load. One of these MAAs includes two serologic assays (the LAg-Avidity assay and the BioRad-Avidity assay; LAg+BR MAA). This MAA has provided accurate incidence estimates in some cohorts [20–22], but has not been evaluated in a setting that includes early/universal ART. The second MAA evaluated in this report is a new MAA that includes the LAg-Avidity assay and a novel two-peptide biomarker (LAG + PepPair MAA). We compared the performance of these two MAAs to the performance of the LAg+VL MAA for estimating HIV incidence and identifying recent infections, using samples and data from the HPTN 071 (PopART) trial.

Methods

Samples used for the analysis

This work was performed using samples and data from two cohorts (Table 1, Fig. 1). The Discovery Cohort was used to develop the LAg+PepPair MAA (Additional file 1). This cohort included 324 longitudinal plasma samples from 57 women in Zimbabwe and Uganda who participated in the Hormonal Contraception and HIV Genital Shedding and Disease Progression Study (GS Study, 2001–2009) [23]; this study included women who acquired HIV infection during the Hormonal Contraception and Risk of HIV Acquisition (HC-HIV) Study (NCT00006324; 1999–2002) [24]. ART was initiated according to local treatment guidelines at the time of the study (CD4 cell count < 250 cells/mL) [23, 24]. The date of HIV seroconversion in this sample set was defined as the midpoint between study visits with the last negative and first positive HIV antibody test, or fifteen days after documentation of acute infection (RNA positive, antibody negative). Data from 14 samples were excluded due to unusually low IgG concentration or unusually high background values on the MSD assay. The final Discovery Cohort included 310 samples (201 samples from participants infected < 1 year; 109 samples from participants infected > 1 year).
The Validation Cohort was used to evaluate the performance of peptide biomarkers for use in MAAs (Additional file 1) and to compare the performance of the $\text{LAG}^+\text{VL}$ MAA, the $\text{LAG}^+\text{BR}$ MAA (previously referred to as the Alternate MAA [20]), and the $\text{LAG}^+\text{PepPair}$ MAA. This cohort included plasma samples from participants in the Population Cohort of HPTN 071 (NCT01900977; 2013–2018), men and women, three arm trial including early/universal ART; prevalent subtype C. The samples used in this report were collected 2 years after the start of the trial (at PC24; sample collection 2016–2017) from participants who were living with HIV at the PC24 visit and had known HIV status one year earlier (at PC12) [27]. Participants who had acute HIV infection at either visit were excluded from analysis. HIV status at the baseline visit (PC0) was available for a subset of participants; these data were used to identify participants who had been living with HIV for > 2 years at the time of sample collection. Samples were collected from 4452 participants who were HIV positive at both PC12 and PC24 visits (non-seroconverters, infected > 2 years); 15,845 participants were HIV-negative at both visits. Fifty-three participants in the non-seroconverter group were excluded from analysis because they were missing data for the LAg-Avidity assay. Twenty-three participants in the non-seroconverter group and two participants in the seroconverter group were excluded due to outlier results for the MSD assay, based on criteria described in Table 1.
in Laboratory Methods. The final Validation Cohort included 4376 non-seroconverters and 219 seroconverters; 3483 (79.6%) of the non-seroconverters were known to be infected >2 years. Sixty-three (28.8%) of the seroconverters and 3205 (73.2%) of the non-seroconverters were virally suppressed at the PC24 visit (viral load ≤400 copies/mL).

Laboratory methods
Testing was performed at the HPTN Laboratory Center (Johns Hopkins University, Baltimore, MD). Testing to determine HIV status and viral load testing were performed previously; viral load testing was performed using the RealTime HIV-1 Viral Load Assay (Abbott Molecular, Des Plaines, IL) with a validated dilution procedure (limit of quantification: 400 copies/mL) [19]. LAg-Avidity values were determined using the HIV-1 Limiting Antigen (LAg)-Avidity EIA (Sedia Biosciences Corporation, Beaverton, OR; LAg-Avidity assay). LAg-Avidity assay results were reported in normalized optical density units (OD-n). The JHU-modified BioRad-Avidity assay was performed as previously described [14]; this assay is based on the Genetic Systems 1/2 ELISA (Bio-Rad Laboratories, Redmond, WA). BioRad-Avidity assay results were reported in avidity index values (AI).

Antibody reactivity to HIV peptides was measured using the MSD U-PLEX assay (Meso Scale Discovery; Rockville, MD) [28]. Peptides were synthesized by LifeTein (Somerset, NJ) and Chi Scientific (Maynard, MA). Antibody reactivity was quantified using U-PLEX-10 plates that were coated with HIV peptides (Additional file 1); the ratio of reactivity to two of these peptides (pep_93621 and pep_92687) is used as a biomarker of HIV infection duration. Antibody reactivity to these peptides was measured using the MSD U‑PLEX assay (Meso Scale Discoveries; Rockville, MD). Stratified random sampling was used to ensure a balance of samples on each plate with high vs. low viral loads (cutoff log10 viral load = 2.5) and long vs. short infection duration based on longitudinal follow-up (cutoff: 1 year). Two samples with high vs. low LAg-Avidity values (high: 2.98 OD-n; low: 0.17 OD-n) were included in triplicate on every plate for quality control. Seven or eight wells per plate included reagents only (no peptide attached) and IgG. Four spots in each well were empty and blocked. MSD signal intensities were analyzed on a log10 transformed scale. For each plate, the 25th and 75th percentile of the log10 transformed signal intensities were calculated for the empty spots, the linker control, and IgG spots; outlier samples with signal intensity values five inter-quartile ranges (IQR) above the 75th percentile or five IQR below the 25th percentile were removed. Antibody reactivity data from the MSD assay were reported as log10 ratios of signal intensity of antibody binding for each pair of peptides. Additive plate effects were eliminated using this approach, since the predictors were ratios of measurements from the same well.

Statistical methods
Data from the Validation Cohort were used to evaluate the performance of three MAAs for cross-sectional HIV incidence estimation and identification of persons with recent HIV infection (the LAg+VL MAA, LAg+BR MAA, and the LAg+PepPair MAA; Table 2). HIV incidence was measured as number of infections per 100 person-years. These estimates were compared to the longitudinal HIV incidence estimate from the HPTN 071 trial between the PC12 and PC24 surveys, which was calculated by dividing observed seroconversions at PC24 by years of follow-up for participants who were HIV-negative at PC12. Incidence estimates and confidence intervals (CIs) were calculated using two methods: first, the method implemented in CEPHIA’s ABIE v3 Incidence Calculator [29], which can be found in the inctools CRAN repository [30], and a second method we

### Table 2  Multi-assay algorithms

| MAA                  | Criteria used to classify samples as “recent”                                                                 | Mean window period |
|----------------------|---------------------------------------------------------------------------------------------------------------|-------------------|
| LAg+VL               | LAg-Avidity < 1.5 OD-n and VL > 1000 copies/mL                                                                 | 130 (118, 142)    |
| LAg+BR               | LAg-Avidity < 2.8 OD-n and BioRad AI < 40%                                                                  | 119 (94, 144)     |
| LAg+PepPair<sup>a</sup> | LAg-Avidity < 2.5 OD-n plus log<sub>10</sub>(peptide pair 4) < −0.02                                           | 102 (69, 159)     |

The table shows the three multi-assay algorithms (MAAs) evaluated in this report. The mean window period is shown in days; 95% confidence intervals are shown in parentheses.

<sup>a</sup> The LAg + PepPair MAA includes the log<sub>10</sub> ratio of antibody reactivity to two HIV peptides as a biomarker of HIV infection duration. Pep_93621 is a 15-amino acid peptide located in gp160; antibody reactivity to this peptide decreases over the course of infection. Antibody reactivity to these peptides was measured using the MSD U-PLEX assay. The value included in the MAA (log<sub>10</sub>(peptide pair 4)) was calculated as: log<sub>10</sub>[(MSD U-PLEX assay result for upgoing gp160 peptide 93621)/[MSD U-PLEX result for downgoing gag peptide 92687]]. Additional file 1 provides additional information on the development and performance of the LAg + PepPair MAA.
have previously described [31–33]. As both methods produced similar results, we present only the results from the first method. The sensitivity and specificity of MAAs for individual-level recency assessments were calculated using known seroconversion status between the PC12 and PC24 visits as the standard for recent vs. non-recent infection. The false recent rate (FRR) was calculated as the percentage of persons classified as recently infected who had been infected >2 years at the time of sample collection [34]. Univariate analyses were performed using the chi-square test without correction.

Informed consent
Written informed consent was obtained from participants prior to enrollment in the GS Study and HPTN 071 (PopART) Population Cohort. The GS Study was approved by ethical review boards at FHI 360, Case Western University, University of California, San Francisco and in Uganda and Zimbabwe. The HPTN 071 (PopART) trial was approved by the institutional review board and ethics committees at the London School of Hygiene and Tropical Medicine, the University of Zambia, and Stellenbosch University. The research reported in this manuscript was performed using stored samples and was approved by the Institutional Review Board of the Johns Hopkins University of Medicine. Research was conducted in accordance with the Declaration of Helsinki.

Results
Study cohorts
Samples and data from the Discovery Cohort (Table 1) were used to identify peptide biomarkers that provided information on the duration of HIV infection and to develop the LAg+PepPair MAA (Additional file 1). Samples and data from the Validation Cohort (Table 1) were used to validate the performance of ratios of antibody reactivity to paired HIV peptides as biomarkers for assessing HIV infection duration. These samples and data were also used to compare the performance of the LAg+VL MAA to two MAAs that do not include viral load as a biomarker: the LAg+BR MAA and the LAg+PepPair MAA (Table 2).

LAG+PepPair MAA development
We previously used a multiplexed antibody profiling system (VirScan) to quantify antibody reactivity to >3300 peptides spanning the HIV genome [25, 35]. We demonstrated that antibody reactivity to specific HIV peptides [25] and ratios of antibody reactivity to paired HIV peptides [26] were correlated with the duration of HIV infection. Peptides identified in those studies were used to develop the LAg+PepPair MAA. A detailed description of the process used for peptide discovery and development of the LAg+PepPair MAA is provided in Additional file 1. Briefly, 11 candidate HIV peptides were identified using VirScan that were differentially targeted by antibodies based on the duration of HIV infection [25, 26]. Four of those peptides were selected for further analysis. Antibody reactivity to synthesized peptides containing corresponding epitopes was quantified using the MSD platform. These data were used to evaluate the performance of 234,000 MAAs that included different combinations of biomarkers (LAG-Avidity, BioRad-Avidity, and/or ratios of antibody reactivity to peptide pairs measured by the MSD assay) with different assay cutoffs. Candidate MAAs were selected that had the highest estimated mean window period with an upper 95% CI for the shadow of <365 days. The final MAA selected was LAg+V-Avidity <2.5 OD-n plus log10(peptide pair 4) < −0.02 (referred to as the LAg+PepPair MAA, Table 2).

Cross-sectional HIV incidence estimation
The LAg+VL MAA, LAg+BR MAA and LAg+PepPair MAA were used to estimate HIV incidence using samples collected in HPTN 071 two years after the start of the study intervention (at the PC24 visit). These results were compared to the longitudinal estimate of HIV incidence based on HIV seroconversion in the second year of the trial (between the PC12 and PC24 visits) (Fig. 2). The longitudinal estimate of HIV incidence was 1.34 events per 100 person-years (95% CI: 1.17–1.53) [18]. The incidence estimate for the LAg+VL MAA obtained using the CEPHIA method was very close to the longitudinal incidence estimate (1.29, 95% CI: 0.97–1.62). The incidence estimates using the CEPHIA method for the LAg+BR MAA and LAg+PepPair MAA were much higher (2.56, 95% CI 2.01–3.11 and 2.84, 95% CI: 1.36–4.32, respectively).

Identification of individuals with recent infection
We next compared the performance of the three MAAs for identifying persons with recent infection (seroconverters, infected <1 year, Table 3). The three MAAs classified different numbers of the 219 seroconverters as recently infected (LAG+VL MAA: 58 [26.5%]; LAg+BR MAA: 80 [36.5%]; LAg+PepPair MAA: 55 [25.1%]). Note that the LAg+BR MAA identified the highest number of participants as recently infected, even though the window period of this MAA was lower than that of the LAg+VL MAA (LAG+VL MAA: 130 days; LAg+BR MAA: 119 days). The three MAAs also misclassified different numbers of the 4376 non-seroconverters as recently infected (LAG+VL MAA: 11 [0.3%]; LAg+BR MAA: 65 [1.5%]; LAg+PepPair MAA: 71 [1.6%]). The FRR (percentage of individuals infected >2 years classified
as recent) was 0.2%, 1.2%, and 1.5% for the LAg+VL MAA, the LAg+BR MAA, and the LAg+PepPair MAA, respectively.

Only 24 (11.0%) of the seroconverters were classified as recently infected by all three MAAs. This is consistent with a prior report that showed that different MAAs identify different subsets of seroconverters as recently infected [7]; the different classification of individual seroconverters as recently infected was not solely due to exclusions for viral load. In this study, 80 of the seroconverters were classified as recent by the LAg+BR MAA. Only 47 (59%) of those participants were also classified as recent by the LAg+VL MAA; 19 of the remaining 33 participants were excluded based on viral load. An overlapping subset of 55 seroconverters was classified as recent by the LAg+PepPair MAA. Only 29 (53%) of those participants were also classified as recent using the LAg+VL MAA; 20 of the remaining 26 participants were excluded based on viral load.

---

**Table 3** Performance of multi-assay algorithms for identifying individuals with recent HIV infection

| Classification | LAg + VL MAAa | LAg + BR MAA | LAg + PepPair MAA |
|----------------|---------------|--------------|-------------------|
| Seroconverters infected < 1 year (N = 219) | 58 | 80 | 55 |
| MAA recent | 160 | 139 | 164 |
| MAA non-recent | 11 | 65 | 71 |
| Non-seroconverters infected > 1 year (N = 4376) | 4365 | 4311 | 4305 |
| MAA recent | 6 | 42 | 51 |
| MAA non-recent | 3477 | 3441 | 3432 |
| Sensitivityb | 26.5% | 36.5% | 25.1% |
| Specificityb | 99.7% | 98.5% | 98.4% |
| Positive predictive valueb | 84.1% | 55.2% | 43.7% |
| Negative predictive valueb | 96.4% | 96.9% | 96.3% |
| False recent ratec | 0.2% | 1.2% | 1.5% |

The table shows the performance characteristics for three multi-assay algorithms (MAAs) for identifying individuals with recent HIV infection (infected < 1 year). The cohort included 219 persons infected < 1 year (seroconverters) and 4376 persons infected > 1 year (non-seroconverters). Sixty-three (28.8%) of the seroconverters and 3205 (73.2%) of the non-seroconverters were virally suppressed (viral load < 400 copies/mL).

---

*a* One participant did not have a viral load result and could not be classified as recent vs. nonrecent by the LAg+VL MAA

*b* Sensitivity, specificity, positive predictive value, and negative predictive value were calculated classifying recent infection as < 1 year since the last negative HIV test

*c* The false recent rate indicates the proportion of participants infected > 2 years who were classified as recently infected.
Table 4  Performance of multi-assay algorithms for classifying seroconverters as recently infected stratified by viral suppression status, age, and gender

|                     | LAg + VL MAA<sup>a</sup> | LAg + BR MAA | LAg + PepPair MAA |
|---------------------|--------------------------|--------------|-------------------|
|                     | Total N = 219            | Recent N = 58 | Nonrecent N = 160 |
| VL status<sup>b</sup> | <0.0001                  | 0.034        | 0.24              |
| Suppressed          | 63                       | 16 (25.4%)   | 19 (30.2%)        |
| Viremic             | 155                      | 63 (40.6%)   | 35 (22.6%)        |
| Age (years)         | 0.57                     | 0.54         | 0.78              |
| 18–24               | 88                       | 30 (34.1%)   | 23 (26.1%)        |
| 25+                 | 131<sup>a</sup>          | 50 (38.2%)   | 32 (24.4%)        |
| Gender              | 0.65                     | 0.67         | 0.83              |
| Female              | 189<sup>a</sup>          | 68 (36.0%)   | 47 (24.9%)        |
| Male                | 30                       | 12 (40.0%)   | 8 (26.7%)         |

The table shows the performance of the LAg + VL MAA, LAg + BR MAA, and LAg + PepPair MAA for classifying the 219 seroconverters from the Validation Cohort as recently infected, stratified by viral suppression status, age, and gender. P-values shown in bold font are statistically significant.

<sup>a</sup> One participant (female, 25+ years) did not have viral load data and could not be classified as recent vs. nonrecent by the LAg+VL MAA.

<sup>b</sup> Viral suppression was defined as having a viral load ≤ 400 copies/mL; one participant did not have viral load determined.
Impact of viral suppression on MAA performance

By design, the LAg + VL MAA classified all participants with viral loads < 1000 copies/mL as having non-recent infection (Table 4). Viral suppression (viral load ≤ 400 copies/mL) significantly impacted the performance of the LAg + BR MAA but not the LAg + PepPair MAA for classifying seroconverters as recently infected (viraemia: 25.4% [16/63] vs. 40.6% [63/155], p = 0.034 for the LAg + BR MAA; 30.2% [19/63] vs. 22.6% [35/155], p = 0.24 for the LAg + PepPair MAA). The majority of the non-seroconverters who were misclassified as recently infected with the LAg + BR MAA and LAg + PepPair MAA were virally suppressed (LAg + BR MAA: 56/65 [86.2%]; LAg + PepPair MAA: 69/71 [97.2%]). However, these persons represented a small proportion of all suppressed non-seroconverters (LAg + BR MAA: 56/3205 [1.7%]; LAg + PepPair MAA: 69/3205 [2.2%]). The performance of the LAg + BR MAA and LAg + PepPair MAA for classifying seroconverters as recently infected was also not impacted by age or gender.

Discussion

This study compared the performance of MAAs for cross-sectional HIV incidence estimation and individual recency assessments using samples and data from HPTN 071 (PopART), a cohort with substantial rates of viral suppression and early ART. This comparison included a widely used MAA that includes viral load (LAG + VL MAA), and two MAAs that do not include viral load (LAG + BR MAA, LAG + PepPair MAA). Despite high levels of ART-induced viral suppression, the LAg + VL MAA provided a point estimate of HIV incidence for this cohort that was nearly identical to the incidence estimate obtained by longitudinal follow-up of the HPTN 071 (PopART) cohort (LAG + VL: 1.29%; longitudinal: 1.34%) [18]. The discrepancy between the performance of this MAA for classifying individuals as recently infected and estimating incidence at a population level may reflect the fact that additional performance characteristics impact population-level incidence estimates (e.g., false recent rate among those with non-recent HIV infection). The two MAAs that did not include viral load provided overestimated incidence predictions (LAG + BR MAA: 2.56%; LAG + PepPair MAA: 2.84%). Of note, while we did obtain a high point estimate of incidence using the LAg + PepPair MAA, the 95% confidence interval for this MAA (1.36–4.32) overlapped with the 95% confidence intervals for the longitudinal incidence estimate (1.17–1.53) and the incidence estimate obtained using the LAg + VL MAA (0.97–1.62).

All three MAAs performed poorly for individual-level recency assessments. The sensitivity for the three MAAs ranged from 25.1% to 36.5%; the low sensitivities, in part, reflect the mean window periods for the MAAs, which range from 102 to 130 days. Of note, the LAg + BR MAA had a shorter mean window period than the LAg + VL MAA (119 vs. 130 days), but identified a higher number of seroconverters as recently infected (80 vs. 58). However, the false recent rate was higher for the LAg + BR MAA than the LAg + VL MAA (1.2 vs. 0.2%). This illustrates the trade-off between identifying more recently infected individuals (sensitivity) and misidentifying those with long-term infection as recently infected (specificity).

By design, the LAg + VL MAA classified all virally suppressed seroconverters as not recently infected. While viral load significantly impacted the identification of seroconverters as recently infected using the LAg + BR MAA, this MAA still classified ~25% of virally suppressed seroconverters as having recent infection. The LAg + BR MAA also correctly classified a higher number of all seroconverters as recently infected compared to the LAg + VL MAA (80 vs. 58). As ART coverage continues to improve, there will be an increasing role for MAAs that do not include viral load as a biomarker and are not impacted by viral suppression. Further research is needed to develop MAAs that provide accurate incidence estimates in those settings. While the LAg + BR MAA did not perform well for cross-sectional incidence estimation, it performed better than the other MAAs for individual-level recency assessments in this cohort. Even so, the low positive predictive value of this MAA (55%) indicates that further research is needed to identify accurate testing approaches for individual-level assessments in settings with high levels of early ART initiation.

Despite our efforts to identify new peptide biomarkers for recency assessments, a MAA that included top-performing peptide biomarkers (LAG + PepPair MAA) did not accurately estimate incidence in the HPTN 071 (PopART) cohort. The sample used to develop the LAg + PepPair was much smaller than the sample set used to develop the LAg + BR MAA (310 vs. 1782 samples) [20], which likely accounted for the broad confidence intervals for the LAg + PepPair MAA. MAAs that provide precise incidence estimates with narrow confidence intervals are needed for estimating HIV incidence, which usually ranges from 1–3%; further analyses using a larger training sample set are needed to fully assess the performance of the PepPair MAA.

While viral suppression did not impact the identification of seroconverters as recently infected using the LAg + PepPair MAA, this MAA still identified fewer seroconverters as recently infected than the LAg + VL MAA or the LAg + BR MAA (50 vs. 58 and 80) and had the highest FRR (1.5%) among the MAAs evaluated. The difference in the FRRs obtained for this MAA in the
Discovery and Validation cohorts might reflect demographic or other differences between the populations.

One limitation of this study is that the Discovery Cohort used for development of the LAg + PepPair MAA did not include any participants who were receiving early ART; in contrast 28.8% of the participants in the Validation Cohort were virally suppressed on ART within the first year of infection. Additionally, the Discovery Cohort included participants with HIV subtypes A, C, and D, while the Validation Cohort included participants with only HIV subtype C. Genetic diversity between subtypes or local HIV strains could potentially influence the performance of peptide-based MAAs. Further validation of these approaches is needed in cohorts with different HIV subtypes to determine the generalizability of these methods. Also, the VirScan assay that was used for peptide discovery only measures antibody reactivity to linear, non-glycosylated peptides; conformational and/or glycosylated HIV epitopes may serve as better biomarkers for estimating the duration of HIV infection. We are also exploring whether antibody reactivity to peptides in the HIV antisense protein [36] could be a useful biomarker for HIV incidence estimation; those peptides were not included in the VirScan phage library used in this report. Finally, study visits for the HPTN 071 (PopART) trial were conducted annually. For calculations of sensitivity and specificity, true positive cases included seroconverters with known infection duration <1 year who were classified as recently infected. As all three MAAs have mean window periods <6 months, only a fraction of such individuals would be expected to be classified as recent. Window periods vary between different populations and cohorts [8, 33, 34, 37–39], and other factors, such as false recent rate and recency distribution profiles, also impact MAA performance. These factors should be considered when evaluating MAA performance.

Conclusion

Two MAAs that did not include viral load as a biomarker did not provide accurate incidence estimates in this study. The LAg + BR MAA was more robust than the widely used LAg + VL MAA for identifying individuals with recent HIV infection and identified many of these persons as recently infected despite viral suppression. Accurate MAAs are needed to track the leading edge of the HIV epidemic and target resources for HIV prevention. The accuracy of MAAs may also impact interpretation of clinical trials and evaluation of HIV prevention programs. Further research is needed to identify robust MAAs that do not include viral load for analysis of populations where most recently infected persons are virally suppressed on ART early in infection.

Abbreviations

AI: Avidity index; ART: Antiretroviral treatment; BR: BioRad-Avidity assay; CI: Confidence interval; FRR: False recent rate; GS Study: Hormonal Contraception and HIV Genital Shedding and Disease Progression Study; HC–HIV Study: Hormonal Contraception and Risk of HIV Acquisition Study; HPTN: HIV Prevention Trials Network; IQR: Inter-quartile range; LAg: Limiting Antigen Avidity assay; MAA: Multi-assay algorithm; MSD: Meso Scale Discovery; OD-n: Optical density units; PLHIV: Persons living with HIV, PY: Person years; VL: Viral load.

Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s12879-022-07850-0.

Additional file 1. Development of the LAg + PepPair MAA.

Acknowledgements

The authors thank the study teams and participants for the parent studies (GS Study, HPTN 071 [PopART]) and the laboratory staff who assisted with sample management and testing.

Author contributions

All authors contributed to the study and to the preparation of the manuscript. In addition, the authors had the following roles in the project. WG-M: performed testing, analyzed data, drafted the manuscript. OL: designed the study, provided input into data analysis. DaM: performed testing, analyzed data. AC: contributed to study design, analyzed data. SEH: performed testing. EP-M: is the HPTN 071 (PopART) Laboratory Center QAQC Representative. RB: provided statistical expertise. DoM: provided statistical expertise, analyzed data. CSM: is the project lead for the GS Study. RH: is the HPTN 071 (PopART) Study Chair. HA: is the HPTN 071 (PopART) Principal Investigator, Zambia. PB: is an HPTN 071 (PopART) South Africa site investigator. BK: provided laboratory support at the Zambia site. KS: is an HPTN 071 (PopART) Zambia site investigator. NM: provided laboratory support at the HPTN 071 (PopART) South Africa site. AvD: provided laboratory support at the HPTN 071 (PopART) South Africa site. IR: provided statistical and bioinformatics expertise, analyzed data. JW: provided statistical and bioinformatics expertise, analyzed data. HBL: designed the study, analyzed data. SHE: designed the study, analyzed data, drafted the manuscript. All authors read and approved the final manuscript.

Funding

This work was supported by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) through R01-AI095068 and the National Institute of General Medical Sciences (NIGMS) through R01-GM136724. Additional support was provided through the Laboratory Center of HIV Prevention Trials Network (HPTN) which is sponsored by the NIAID under Cooperative Agreements UM1-AI068619, UM1-AI068617 and UM1-AI068613, with funding from the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR). Additional support was provided by the Division of Intramural Research, NIAID. Additional funding for the HPTN 071 (PopART) trial was provided by the International Initiative for Impact Evaluation (3ie) with support from the Bill & Melinda Gates Foundation, as well as by NIAID, the National Institute on Drug Abuse (NIDA) and the National Institute of Mental Health (NIMH), all part of NIH. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIAID, NIMH, NIDA, PEPFAR, 3ie or the Bill & Melinda Gates Foundation. Richard Hayes also received support from the UK Medical Research Council (MRC) and the UK Department for International Development (DFID) under the MRC/DFID Concordat agreement, which is also part of the EDCTP2 programme supported by the European Union (MR/R010161/1).

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.
Declarations

Ethics approval and consent to participate
Written informed consent was obtained from participants prior to enrollment in the G5 Study and HPTN 071 (PopART) Population Cohort. The G5 Study was approved by ethical review boards at FHI 360, Case Western University, University of California, San Francisco and in Uganda and Zimbabwe. The HPTN 071 (PopART) trial was approved by the institutional review board and ethics committees at the London School of Hygiene and Tropical Medicine, the University of Zambia, and Stellenbosch University. The research reported in this manuscript was performed using stored samples and was approved by the Institutional Review Board of the Johns Hopkins University of Medicine. Research was conducted in accordance with the Declaration of Helsinki.

Consent for publication
Not applicable.

Competing interests
H.B.L. is an inventor on an issued patent (US20160320406A) filed by Brigham and Women's Hospital that covers the use of the ViRScan technology, is a founder of ImmuneID, Portal Bioscience and Alchemab, and is an advisor to TScan Therapeutics. All other authors declare that they have no competing interests.

Author details
1Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. 2Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Baltimore, MD, USA. 3Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA. 4Department of Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, USA. 5Department of Biostatistics, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA. 6Department of Biostatistics, UCLA Fielding School of Public Health, Los Angeles, CA, USA. 7Department of Clinical Pathology, UC Davis School of Medicine, Davis, CA, USA. 8Behavioral, Epidemiologic, and Clinical Sciences, Durham, NC, FHI 360, USA. 9Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK. 10Zambart, University of Zambia School of Public Health, Lusaka, Zambia. 11Clinical Research Department, London School of Hygiene and Tropical Medicine, London, UK. 12Desmond Tutu TB Center, Department of Paediatrics and Child Health, Stellenbosch University, Stellenbosch; Western Cape, South Africa. 13Division of Biostatistics and Bioinformatics, Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Received: 17 November 2021 Accepted: 7 November 2022
Published online: 11 November 2022

References
1. Brookmeyer R, Konikoff J, Laeyendecker O, Eshleman SH. Estimation of HIV incidence using multiple biomarkers. Ann J Epidemiol. 2013;177(3):264–72.
2. Brookmeyer R, Laeyendecker O, Donnell D, Eshleman SH. Cross-sectional HIV incidence estimation in HIV prevention research. J Acquir Immune Defic Syndr. 2013;63(Suppl 2):S233–9.
3. Laeyendecker O, Brookmeyer R, Donnell D, Eshleman SH. HIV incidence determination in the United States: a multiasay approach. J Infect Dis. 2013;207(2):232–9.
4. Laeyendecker O, Piwowar-Manning E, Fiamma A, Kulich M, Donnell D, Bassuk S, et al. Estimation of HIV incidence in a large, community-based, randomized clinical trial: NMIM project accept (HIV Prevention Trials Network 043). PLoS ONE. 2013;8(7):e68834.
5. Coates TJ, Kulich M, Celentano DD, Zelaya CE, Charyalatertas S, Chingono A, et al. Effect of community-based voluntary counselling and testing on HIV incidence and social and behavioural outcomes (NMIM Project Accept; HPTN 043): a cluster-randomised trial. Lancet Glob Health. 2014;2(5):e267–77.
6. Eshleman SH, Hughes JP, Laeyendecker O, Wang J, Brookmeyer R, Johnson-Lewis L, et al. Use of a multifaceted approach to analyze HIV incidence in a cohort study of women in the United States: HIV Prevention Trials Network 044 Study. J Infect Dis. 2013;207(2):223–31.
7. Grant-McAuley W, Klock E, Laeyendecker Q, Piwowar-Manning E, Wilson E, Clarke W, et al. Evaluation of multi-assay algorithms for identifying individuals with recent HIV infection. HPTN 071 (PopART). PLoS ONE. 2021;16(12): e0258644.
8. Duong YT, Kassanjee R, Welte A, Morgan M, De A, Dobbs T, et al. Recalibration of the limiting antigen avidity EIA to determine mean duration of recent infection in divergent HIV-1 subtypes. PLoS ONE. 2015;10(2): e014947.
9. Wei X, Liu X, Dobbs T, Kuehl D, Nkenagasong JN, Hu DJ, et al. Development of two-avidity-based assays to detect recent HIV type 1 seroconversion using a multistubtype gp41 recombinant protein. AIDS Res Hum Retroviruses. 2010;26(1):61–71.
10. WHO/UNAIDS. 2014. Annual meeting of the technical working group on HIV incidence assays. https://apps.who.int/iris/bitstream/handle/10665/162156/WHO_HIV_2015_11_eng.pdf;sequence=1. Accessed Sept 2021.
11. Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. WHO guidelines approved by the guidelines review committee. Geneva 2015. https://www.ncbi.nlm.nih.gov/books/NBK327113/. Accessed Sept 2021.
12. WHO/UNAIDS. 2015. Understanding Fast-Track: Accelerating action to end the AIDS epidemic by 2030. https://www.unaids.org/sites/default/files/media_asset/201506_IC2743_Understanding_FastTrack_en.pdf. Accessed Jun 2021.
13. Klock E, Mwinyi N, Eller LA, Fernandez RE, Kibuku HA, Ntayaphan S, et al. Impact of early antiretroviral treatment initiation on performance of cross-sectional incidence assays. AIDS Res Hum Retroviruses. 2020;36(7):583–9.
14. Laeyendecker O, Latimore A, Eshleman SH, Summermont J, Oliver AE, Gamiel J, et al. The effect of sample handling on cross sectional HIV incidence testing results. PLoS ONE. 2011;6(10): e25899.
15. Longoz A, Mehta SH, Kirk GD, Margolick JB, Brown J, Quinn TC, et al. Incorrect identification of recent HIV infection in adults in the United States using a limiting-antigen avidity assay. AIDS. 2014;28(8):1227–32.
16. Wendel SK, Longoz AF, Eshleman SH, Blankson JN, Moore RD, Keruly JC, et al. Short communication: the impact of viral suppression and viral breakthrough on limited-antigen avidity assay results in individuals with clade B HIV infection. AIDS Res Hum Retroviruses. 2020;36(7):583–9.
17. Wendel SK, Mullis CE, Eshleman SH, Blankson JN, Moore RD, Keruly JC, et al. Effect of natural and ARV-induced viral suppression and viral break- through on anti-HIV antibody proportion and avidity in patients with HIV-1 subtype B infection. PLoS ONE. 2013;8(2): e55525.
18. Klock E, Wilson F, Fernandez RE, Piwowar-Manning E, Moore A, Kosloff B, et al. Evaluation of population-level HIV-1 incidence estimation by cross-sectional incidence assays in the HPTN 071 (PopART) trial. J Int AIDS Soc. 2021;24(12): e25830.
19. Hayes RJ, Donnell D, Floyd S, Mandla N, Bivalya J, Sabapathy K, et al. Effect of universal testing and treatment on HIV incidence—HPTN 071 (PopART). N Engl J Med. 2019;381(3):207–18.
20. Konikoff J, Brookmeyer R, Longoz AF, Cousins MM, Celum C, Buchbinder SP, et al. Performance of a limiting-antigen avidity enzyme immunoassay for cross-sectional estimation of HIV incidence in the United States. PLoS ONE. 2013;8(12): e82772.
21. Sharma S, Schlusser KE, de la Torre R, Tambussi G, Draenert R, Pinto AN, et al. The benefit of immediate compared with deferred antiretrovi- ral therapy on CD4+ cell count recovery in early HIV infection. AIDS. 2019;33(8):1335–44.
22. Tuen M, Bimela JS, Banin AN, Ding S, Harkins GW, Weiss S, et al. Immediate correlates of disease progression in linked HIV-1 infection. Front Immunol. 2019;10:1062.
23. Morrison CS, Chen PL, Nankyia J, Rinaldi A, Van Der Pol B, Ma YR, et al. Hormonal contraceptive use and HIV disease progression among women in Uganda and Zimbabwe. J Acquir Immune Defic Syndr. 2011;57(2):157–64.
24. Morrison CS, Richardson BA, Mmiko F, Chiapato T, Celentano DD, Luoto J, et al. Hormonal contraception and the risk of HIV acquisition. AIDS. 2007;21(1):85–95.
25. Eshleman SH, Laeyendecker O, Kammers K, Chen A, Sivay MV, Kottapalli S, et al. Comprehensive profiling of HIV antibody evolution. Cell Rep. 2019;27(5):1422-33.e4.

26. Chen A, Laeyendecker O, Eshleman SH, Monaco DR, Kammers K, Larman HB, et al. A top scoring pairs classifier for recent HIV infections. Stat Med. 2021;40(11):2604–12.

27. Eshleman SH, Piwowar-Manning E, Wilson EA, Lennon D, Fogel JM, Agyei Y, et al. Determination of HIV status and identification of incident HIV infections in a large, community-randomized trial: HPTN 071 (PopART). J Int AIDS Soc. 2020;23(2): e25452.

28. Meso Scale Discovery. 2021. MULTI-ARRAY technology. https://www.mesoscope.com/en/technical_resources/our_technology/multi-array. Accessed 25 May 2021.

29. Kassanjee R, McWalter TA, Barnighausen T, Welte A. A new general biomarker-based incidence estimator. Epidemiology. 2012;23(5):721–8.

30. Grebe E, Welte A, McIntosh A, Baumler P and Ongarello S. inctools: incidence estimation tools. R package version 1.0.15. 2019. https://CRAN.R-project.org/package=inctools. Accessed Aug 2021.

31. Brookmeyer R. Accounting for follow-up bias in estimation of human immunodeficiency virus incidence rates. J Roy Stat Soc a Sta. 1997;160:127–40.

32. Brookmeyer R, Quinn TC. Estimation of current human immunodeficiency virus incidence rates from a cross-sectional survey using early diagnostic tests. Am J Epidemiol. 1995;141(2):166–72.

33. Laeyendecker O, Konikoff J, Morrison DE, Brookmeyer R, Wang J, Celum C, et al. Identification and validation of a multi-assay algorithm for cross-sectional HIV incidence estimation in populations with subtype C infection. J Int AIDS Soc. 2018. https://doi.org/10.1002/jia2.25082.

34. Kassanjee R, Pilcher CD, Keating SM, Facente SN, McKinney E, Price MA, et al. Independent assessment of candidate HIV incidence assays on specimens in the CEPHIA repository. AIDS. 2014;28(16):2439–49.

35. Xu GJ, Wu T, Xu Q, Li MZ, Vernon SD, Ndungu T, et al. Viral immunology. Comprehensive serological profiling of human populations using a synthetic human virome. Science. 2015;348(6239):696.

36. Savoret J, Mesnard JM, Gross A, Chazal N. Antisense transcripts and antisense protein: a new perspective on human immunodeficiency virus type 1. Front Microbiol. 2020;11: 620941.

37. Gonese E, Klimax PH, van Schalkwyk C, Grebe E, Mutasa K, Ntozini R, et al. Evaluation of the performance of three biomarker assays for recent HIV infection using a well-characterized HIV-1 subtype C incidence cohort. AIDS Res Hum Retroviruses. 2019;35(7):615–27.

38. Hargrove JW, van Schalkwyk C, Humphrey JH, Mutasa K, Ntozini R, Owen SM, et al. Short communication: heightened HIV antibody responses in postpartum women as exemplified by recent infection assays: implications for incidence estimates. AIDS Res Hum Retroviruses. 2017;33(9):902–4.

39. Longosz AF, Morrison CS, Chen PL, Brand HH, Arts E, Nankya I, et al. Comparison of antibody responses to HIV infection in Ugandan women infected with HIV subtypes A and D. AIDS Res Hum Retroviruses. 2015;31(4):421–7.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.